HERVolution Therapeutics Secures $11.7 Million to Revolutionize Immunotherapy for Aging and Cancer Treatments

HERVolution Therapeutics ApS, a biotechnology company specializing in the dark genome, has successfully raised $11.7 million in a Series A funding round aimed at propelling forward its innovative immunotherapies. The financing, led by Serum Institute of India (SII), accompanied by participation from the European Innovation Council (EIC) Fund, underscores the significant confidence investors have in HERVolution's capabilities to address serious health challenges associated with aging, cancer, and metabolic diseases.

The funds raised will primarily be utilized to further the clinical development of its lead therapeutic assets beginning with encouraging validation of their human endogenous retroviruses (HERVs) targeting approach. This strategic investment will facilitate the necessary steps to initiate clinical evaluations, aimed for 2025, as HERVolution works towards advancing its therapies from the lab to effective treatment options for patients.

What Are HERVs?

HERVs are genetic remnants of ancient viral infections that have long since integrated into our genomes. Although typically dormant, these elements might become active due to age or disease, presenting unique opportunities and challenges in medical science. They have been implicated in various conditions including cancer, Type 2 diabetes, and amytrophic lateral sclerosis (ALS), alongside emerging roles linked to the aging process. Despite the apparent relevance, leveraging HERVs as therapeutic targets has been a formidable endeavor because they are recognized by the immune system as